SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 53.85-4.5%Jan 9 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: BulbaMan who wrote (9111)9/11/2003 5:16:12 PM
From: Michael Young  Read Replies (1) of 52153
 
<< And, neither Aventis or Genta seem likely to be companies that would go out on a limb for a drug they knew was ineffective.
>>

I think both would certainly spin lackluster results and hope for the best. I wouldn't expect them to call it quits, even if they privately realize they odds of approval are small. Biotechs are (unfortunately) notorius for playing these games with the investment community.

I get weary of bio execs talking about great trial designs and strong endpoints as the trial is in progress. Then the results come in and suddenly there were problems with the trial parameters that kept the wonder drug from hitting the primary endpoint.

MIKE
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News